Document is current
Any future updates will be listed below
-
Authors
Meca-Lallana, José Eustasio https://orcid.org/0000-0001-5050-9890
Eichau, Sara
Casanova, Bonaventura
Rodríguez, Elena Álvarez
Pato, Antonio
Forner, Mireia
Toledo, Baldo
-
Funding
Funding for this research was provided by:
Sanofi España (Sanofi España)
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 3 December 2024
First Online: 18 December 2024
Declarations
:
: This study was approved by the Ethics Committee of Hospital Clínico San Carlos (Madrid, Spain). All patients were informed and gave written informed consent to participate.
: Not applicable.
: JEML declares grants and consulting or speaking fees from Almirall, Biogen, Celgene, Genzyme, Merck, Novartis, Roche and Teva; SE declares speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche and Teva; BC declares grants from Sanofi Genzyme, Novartis, Merck, Roche, Biogen-Idec and Bristol-Myers-Squib; EAR declares consulting fees (Almirall, Bayer, Biogen, Novartis, Sanofi, Merck, Teva and Roche); AP declares personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Sanofi, Almirall, Bayer, Roche, Merck; MF and BT are Sanofi employees with ownership interest.
